Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation ...

Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024. Sanofi and Orano Med, a subsidiary of the ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the ...

PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine ...